title: [Bacteraemia and sepsis].
abstract: Recent news in the field of bloodstream infection and sepsis relevant for the practitioner include the recommendation in the newly revised German sepsis guideline to introduce selective intestinal decontamination with non-absorbable antimicrobial substances for the prevention of secondary infections in ventilated patients. This intervention, however, remains controversial because there are indications of unfavourable effects (increased development of resistance), and because the effect size has been rather low. Other news indicate not only that procalcitonin can be reasonably used as an aid to determine the duration of antibiotic treatment in community-acquired respiratory infection and pneumonia. A procalcitonin-based algorithm can also be used in critical care patients to shorten the duration of antibiotic administration without worsening outcomes. Recent data indicate that E. coli and S. aureus continue to be the most frequent pathogens isolated in bloodstream infection. The proportion of E. coli strains producing extended-spectrum beta lactamase (ESBL) is increasing. New epidemiologic evidence shows that infections with this pathogen, resistant to many standard antibiotics, are associated with an increased mortality rate, similar to infections due to methicillin-resistant Staphylococcus aureus (MSRA). The incidence of MRSA bacteraemia in Germany can now be estimated better as it has become a notifiable infection.
authors.affiliation: Zentrum Infektiologie und Reisemedizin, Medizinische Universitätsklinik. 79106 Freiburg. kern@if-freiburg.de
authors.forename: W V
authors.initials: WV
authors.lastname: Kern
mesh_terms: D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy*; D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D003422:Critical Care; D003428:Cross Infection / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D003430:Cross-Sectional Studies; D024901:Drug Resistance, Multiple, Bacterial; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D005858:Germany; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D009894:Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy; D017410:Practice Guidelines as Topic; D011498:Protein Precursors / Q000097:blood; D018805:Sepsis / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy*; D013156:Splenectomy; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide